MedTrace Logo

The Effects of Minimal Shoes in Older People at Risk of Falls: The Feetback Shoe Study

NCT03874728 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-07-07

No results posted yet for this study

Summary

A third of people over 65, and half of people over 80, fall at least once a year. Falls are the most common cause of death from injury in the over 65s and result in a significant financial burden on the whole society. Shoes directly influence balance, gait, and the subsequent risk of slips, trips and falls by altering somatosensory feedback to the foot and ankle. Minimal shoes, that is shoes lacking a firm heel cup, a rigid sole or longitudinal arch support, have shown advantages in strengthening muscles and improving balance as compared to conventional shoes. However, limited research has studied the effect of minimal shoe in older people at risk of falls. The aim of the project will be to assess the effects of minimal shoes in older people at risk of falls, compared to conventional shoes and barefoot.

Conditions

  • Falls
  • Aging

Interventions

OTHER

Minimal shoes

A minimal shoe (Vivobarefoot Ltd., London, UK) will be used.

OTHER

Standardised conventional shoes

The Go Walk 4.0-Pursuit shoe for women (Skechers USA, Inc.) and the Superior 2.0-Jeveno shoe for men (Skechers USA, Inc) will be used.

OTHER

Barefoot

Participants will conduct the assessments barefoot.

OTHER

"Smart" shoe insoles

Arion pressure-measuring insoles (Eindhoven, The Netherlands) will be used in the study.

Sponsors & Collaborators

  • Liverpool University Hospitals NHS Foundation Trust

    collaborator OTHER_GOV

  • University of Liverpool

    lead OTHER

Principal Investigators

  • Kristiaan D'Août, PhD · University of Liverpool

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-20
Primary Completion
2020-03-01
Completion
2020-03-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03874728 on ClinicalTrials.gov